# Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

> **NCT05646316** · PHASE3 · RECRUITING · sponsor: **NRG Oncology** · enrollment: 428 (estimated)

## Conditions studied

- Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Diagnostic Imaging Testing
- **PROCEDURE:** Excisional Biopsy
- **DRUG:** Indocyanine Green Solution
- **PROCEDURE:** Minimally Invasive Surgery
- **PROCEDURE:** Pelvic Lymphadenectomy
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Sentinel Lymph Node Mapping

## Key facts

- **NCT ID:** NCT05646316
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-07
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 428 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05646316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05646316, "Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05646316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*